Loading...
Clinical Takeaway
: This plasma biomarker panel increased diagnostic confidence but rarely changed diagnoses, and intermediate results remained common.Context
Distinguishing Alzheimer’s disease from other neurodegenerative disorders can require costly or invasive tests, such as amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis. Plasma biomarkers offer a less-invasive alternative, but their performance varies by assay.
In this prospective diagnostic study of 450 patients at three memory clinics, multidisciplinary teams recorded suspected syndrome, etiology, and diagnostic confidence after standard clinical, neuropsychological, and MRI evaluations, and again after reviewing a plasma biomarker panel of phosphorylated tau 181 (p-tau181), glial fibrillary acidic protein, and neurofilament light chain.
Key Results
The median diagnostic confidence increased from 80% to…